Hjem
Universitetet i Bergen
Øystein Fløttens bilde

Øystein Fløtten

Førsteamanuensis
Klinisk institutt 2
  • E-postoystein.flotten@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2023). “The challenge is the complexity” – A qualitative study about decision-making in advanced lung cancer treatment. Lung Cancer. 8 sider.
  • Vis forfatter(e) (2023). Pleural Empyema Caused by Streptococcus intermedius and Fusobacterium nucleatum: A Distinct Entity of Pleural Infections. Clinical Infectious Diseases. 1361-1371.
  • Vis forfatter(e) (2022). Trajectory of health-related quality of life during the last year of life in patients with advanced non-small–cell lung cancer. Supportive Care in Cancer. 9351-9358.
  • Vis forfatter(e) (2022). Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer. Lung Cancer. 49-57.
  • Vis forfatter(e) (2021). High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. The Lancet Oncology. 321-331.
  • Vis forfatter(e) (2020). Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC. Acta Oncologica.
  • Vis forfatter(e) (2018). Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement. Anticancer Research. 871-876.
  • Vis forfatter(e) (2018). Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials. Acta Oncologica. 1574-1579.
  • Vis forfatter(e) (2018). A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer. European Journal of Clinical Nutrition. 1-8.
  • Vis forfatter(e) (2017). Muscle mass and association to quality of life in non-small cell lung cancer patients. Journal of Cachexia, Sarcopenia and Muscle. 759-767.
  • Vis forfatter(e) (2017). Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer. e129-e136.
  • Vis forfatter(e) (2016). Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer. Lung Cancer. 9-14.
  • Vis forfatter(e) (2016). Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Annals of Oncology. 1291-1298.
  • Vis forfatter(e) (2016). Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Annals of Oncology. 225-232.
  • Vis forfatter(e) (2016). Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clinical Nutrition. 1386-1393.
  • Vis forfatter(e) (2016). Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncologica. 591-597.
  • Vis forfatter(e) (2016). Oral versus intravenous vinorelbine in advanced NSCLC - a retrospective comparison. Cancer Treatment and Research Communications. 15-20.
  • Vis forfatter(e) (2016). Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer. Acta Oncologica. 1349-1354.
  • Vis forfatter(e) (2015). Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer. 85-91.
  • Vis forfatter(e) (2013). Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group. British Journal of Cancer. 1467-1475.
  • Vis forfatter(e) (2012). Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. British Journal of Cancer. 442-447.
  • Vis forfatter(e) (2012). A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. Lung Cancer. 63-69.
  • Vis forfatter(e) (2010). Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. European Journal of Cancer. 2225-2234.
  • Vis forfatter(e) (2009). A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer. 88-93.
Brev til redaktøren
  • Vis forfatter(e) (2022). Characteristics and survival of patients with non-small cell lung cancer treated with immune-checkpoint inhibitors in the real-world: experiences from Bergen, Norway. Acta Oncologica. 814-818.
Doktorgradsavhandling
  • Vis forfatter(e) (2019). Simplifying Treatment of Advanced Non-small Cell Lung Cancer. Regimen, Route of Administration, and Patients' Preferences .
Sammendrag/abstract
  • Vis forfatter(e) (2015). Survival of patients with N3 lymph node disease in a cohort with limited disease small-cell lung cancer receiving concurrent chemoradiotherapy. Journal of Thoracic Oncology. s744.
  • Vis forfatter(e) (2015). Reduction in tumor size after the first course of cisplatin/etoposide (PE) in limited disease small-cell lung cancer (LD SCLC). Journal of Clinical Oncology.
  • Vis forfatter(e) (2015). Associations between Comorbidity, Treatment Toxicity and Overall Survival in Limited Disease Small-Cell Lung Cancer (LD-SCLC). Journal of Thoracic Oncology. s744.
  • Vis forfatter(e) (2012). Randomized phase II trial comparing two schedules of thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC). Journal of Clinical Oncology. 1 sider.
  • Vis forfatter(e) (2011). Randomized Phase Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer: The MENZA Study. European Journal of Cancer. 640-640.
Poster
  • Vis forfatter(e) (2018). Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small- cell lung cancer.
  • Vis forfatter(e) (2015). Association between comorbidity, treatment toxicity and overall survival in limited disease small-cell lung cancer.
  • Vis forfatter(e) (2012). Phase II Trial Comparing Two Schedules of Thoracic Radiotherapy in Limited Disease Small-Cell Lung Cancer.
  • Vis forfatter(e) (2011). Randomized Phase Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer: The MENZA Study.
  • Vis forfatter(e) (2010). Phase III study comparing vinorelbine-gemcitabine with vinorelbine-carboplatin as first-line chemotherapy of advanced NSCLC: A Norwegian Lung Cancer Study Group trial.
  • Vis forfatter(e) (2010). Phase III study comparing vinorelbine-gemcitabine with vinorelbine-carboplatin as first-line chemotherapy of advanced NSCLC: A Norwegian Lung Cancer Study Group trial.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2017). Implementation of lung cancer CT screening in the Nordic countries. Acta Oncologica. 1249-1257.
Nettsider (opplysningsmateriale)
  • Vis forfatter(e) (2013). Nasjonal handlingsplan for lungekreft (for Helsedirektoratet, HD og Norwegian Lung Cancer Group, NLCG) - utredning og behandling (utredningskapittelet).

Se fullstendig oversikt over publikasjoner i CRIStin.